# AMPLITUDE (NCT04497844)

> A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

No report yet. It can be ordered.

- Drugs tested: niraparib
- Indication: HRR-deficient metastatic castration-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04497844
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Prostatic Neoplasms
- Interventions: Niraparib+ Abiraterone acetate fixed dose combination (FDC); Abiraterone acetate (AA); Prednisone; Placebo FDC; Placebo AA
- Enrollment: 696
- Primary outcome: Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator
- Primary outcome: HRR Effector Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator
- Primary outcome: All HRR: Radiographic Progression-free Survival (rPFS) Assessed by Investigator

## Indexed commentary on AMPLITUDE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=amplitude-nct04497844